Articles tagged with Ovarian Cancer
Researchers found that hormonal maintenance therapy significantly improved survival in women with low-grade serous carcinoma of the ovary/peritoneum. Women who received HMT showed an average progression-free survival of 64.9 months, compared to 26.4 months for those in the surveillance group.
Researchers developed a new tool to analyze genetic changes in ovarian cancer, revealing pathways disrupted by the loss and gain of genes. The study found that targeting autophagy genes showed promise in treating chemotherapy-resistant disease.
Researchers will utilize a unique odor signature to create a portable screening device for early-stage ovarian cancer diagnosis. The project aims to improve survival rates by identifying the disease at its initial stages.
A new study has found that defects in the EMSY gene, similar to BRCA genes, spur cancer growth independently of BRCA1 and BRCA2 protection. The research suggests new treatment options for women with normal BRCA genes who develop breast and ovarian cancer.
The study found that the BRCA1 gene is required for the survival of blood forming stem cells, which could explain why patients with BRCA1 mutations do not have an elevated risk for leukemia. The researchers also suggest that these patients may have a tougher time with chemotherapy side effects.
Researchers developed a blood test to predict ovarian cancer patients' response to chemotherapy using tumour DNA levels. The test identified patients whose tumour DNA count dropped by more than half after one cycle of chemotherapy as those likely to respond well to treatment.
Researchers found correlations between circulating tumor DNA (ctDNA) levels and ovarian cancer size, as well as patient response to treatment. The study used ctDNA carrying mutations in the TP53 gene to predict disease progression and treatment response, offering potential for early diagnosis and alternative treatment options.
A 15-year study of prostate cancer patients found little difference in mortality between those screened annually and those not screened. However, the data suggest that personalized screening strategies could identify men at higher risk of death from other diseases.
Researchers identified a molecule called AXL which triggers the spread of an aggressive form of ovarian cancer. Blocking AXL may be an effective treatment option for patients with Mes subtype ovarian cancer.
Researchers at Case Western Reserve University developed a new method called InFlo to assess cell communication networks and identify disease-specific anomalies. InFlo predicts how cells send signals across networks to cause cancer or other disease, with applications in basic and translational research.
Researchers at Georgia Tech develop a targeted therapy using nanoparticles to deliver short interfering RNA that knocks down EGFR protein, leading to massive reduction or complete eradication of ovarian cancer tumors. The treatment, combined with chemotherapy, shows promising results in limited in vivo tests on mice.
Researchers at The Wistar Institute have developed a combination therapy that improves chemoresistance in ovarian cancer. BET inhibitors can suppress ALDH activity, making treatment more effective when used with cisplatin. This approach has shown extended survival rates and delayed tumor growth in mice.
Researchers at Boston University School of Medicine have discovered a potential treatment option for ovarian cancer by combining calpeptin with epigenetic inhibitors. The therapy shows promise in killing cancer cells and preventing their growth, offering new hope for women affected by the disease.
Research from Kumamoto University has discovered that a natural compound isolated from onions, onionin A, exhibits anti-ovarian cancer properties. ONA inhibits the growth of ovarian cancer cells and enhances the effects of anti-cancer drugs, making it a promising treatment option.
PharmaMar announces completion of Phase 3 pivotal study CORAIL with lurbinectedin (PM1183) for platinum-resistant ovarian cancer. The study demonstrates potential therapeutic alternative for patients who relapse after standard treatment. PharmaMar has successfully recruited 443 patients from over 100 hospitals in Europe and the USA.
New research from The Wistar Institute found that estrogen signaling is responsible for immunosuppressive effects in the tumor microenvironment across various cancers. This discovery paves the way for combining anti-estrogen therapy with immunotherapeutic treatments to extend survival in patients.
The ENGOT-OV16/NOVA trial shows niraparib significantly improves progression-free survival in recurrent ovarian cancer patients, with median survival rates up to 21 months. Niraparib also improves secondary endpoints, including time to first subsequent treatment and chemotherapy-free interval.
Researchers at The Wistar Institute discovered that BET inhibitors can suppress PD-L1 activity, a major therapeutic target in various tumors. This approach may reduce side effects while enhancing the immune response against cancer.
Global trends show a decline in ovarian cancer deaths in the EU and USA between 2002 and 2012, with declines also seen in Australia and New Zealand. The main reason is the use of oral contraceptives, which provide long-term protection against ovarian cancer.
The Independent Data Monitoring Committee approved PharmaMar's CORAIL study of PM1183 in patients with platinum-resistant ovarian cancer. The pivotal Phase III trial evaluates the efficacy of PM1183 compared to standard treatments.
A recent study by the Medical University of South Carolina found that African American women with lower socioeconomic status are at a higher risk of developing ovarian cancer. The study revealed a significant inverse association between SES and ovarian cancer risk, with women having a college degree or higher experiencing a 29% lower r...
Researchers have found a way to detect ovarian cancer early using a protein test, providing new hope for patients. An enzyme called SIK2 has been identified as key in making ovarian cancer more deadly, offering a potential new treatment target.
Researchers have identified BRCA1 mutations that predict treatment resistance in breast and ovarian cancers. Studies found that tumors with these mutations express a RING-deficient BRCA1 protein, leading to poor treatment responses.
Researchers at Mayo Clinic developed a new method to detect ovarian cancer recurrence using liquid biopsies from blood tests and DNA sequencing. This approach allows for earlier intervention and more effective individualized treatment by monitoring genetic changes in circulating cell-free DNA.
A new streamlined approach to genetic testing for women with ovarian cancer allows for faster and more affordable testing, enabling personalized cancer management and cancer prevention strategies. The test has been widely adopted in the UK and internationally, with estimates suggesting it could save £2.6M per year.
A new study shows that removing fallopian tubes during hysterectomies can help prevent ovarian cancer without compromising surgical outcomes. The procedure has been widely adopted in Kaiser Permanente's Northern California system, with no increase in complications or length of stay.
Researchers at Cold Spring Harbor Laboratory have identified a new pathway in ovarian cancer cells that can be targeted by drugs, reducing metastasis. The newly uncovered pathway depends on activity of protein FER, which activates receptor MET, leading to elevated motility and invasiveness.
A new study published in ecancermedicalscience found that online information about ovarian cancer can cause as much worry as comfort for women at high risk. The researchers suggest that patients should seek guidance from healthcare professionals and credible websites to make informed decisions.
A study published in JAMA Oncology found that women with the BRCA1 gene mutation have a significantly higher risk of developing serous endometrial cancer, which has a mortality rate of 50%. The study suggests that women with this genetic mutation should consider removing their uterus along with their ovaries and fallopian tubes. Resear...
A recent study has identified over 200 proteins involved in cell movement and immune system function that are implicated in ovarian cancer progression. By analyzing the proteomes of 169 ovarian cancer patients, researchers have gained new insights into the biology of the disease and potential targets for treatment.
Scientists analyzed 169 ovarian cancer tumors to identify key proteins, revealing new molecular events in high-grade serous carcinoma. This proteogenomics approach combines genomic and proteomic data to improve understanding of the disease, with potential applications for precision medicine and pharmaceutical interventions.
Researchers found a strong five-gene signature in all patients who succumbed to the disease, regardless of their length of survival. The team also tested HXR9, which blocked HOX gene function, forcing cancer cells to close down and die, and found that combining it with cisplatin significantly increased cancer cell killing.
Researchers propose reducing the threshold for pre-emptive surgery on women at high risk of ovarian cancer from 10% to 4%. This could add up to 43 extra days of life expectancy if hormone replacement therapy is taken. The procedure would be cost-effective and help compensate for the lack of a reliable test.
Research reveals five major ways microRNAs contribute to chemoresistance in epithelial ovarian cancer (EOC). Targeting cell cycle regulation, apoptosis, drug transporters, tumor suppressor roles, and signaling pathways can help reverse resistance. This knowledge highlights the therapeutic potential of miRNAs.
A ketogenic diet has shown promise in reducing tumor size and progression in ovarian cancer, with a new clinical trial aiming to replicate these results in humans. The trial aims to investigate the effects of a low-carbohydrate diet on ovarian cancer patients' quality of life and cancer-related measures.
Research suggests that patients with advanced ovarian cancer who underwent pre-surgical chemotherapy showed altered immune cells in their tumors, indicating a potential increase in effectiveness of immunotherapy after treatment. This study found evidence of activation of certain T cells and reduction of immune suppressive cells in pati...
Researchers discovered that chemotherapy activates immune cells T cells within tumours, but also boosts cancer defences against immune attack. Effective immunotherapy treatments will have to block PD-L1 protein to target tumours effectively.
A study published at the American Society of Clinical Oncology Annual Meeting found bacteria in women's ovaries and fallopian tubes. Women with ovarian cancer have distinct bacterial profiles, suggesting potential links to cancer development or progression.
Dr. Glen Weiss presents five innovative cancer studies at ASCO, including liquid biopsies for predicting treatment improvements and promising results with avelumab against recurrent-refractory ovarian cancer. Brigatinib shows substantial antitumor activity in ALK non-small cell lung cancer patients.
Researchers found that nearly half of women over 75 with stage III/IV cancer do not have surgery, while black and American Indian women are 35% less likely to receive surgery than white women. Surgical treatment is associated with a fourfold increase in survival for patients.
Researchers are developing imaging biomarkers and optical imaging tools to screen for ovarian cancer, a 'silent killer' of women. The goal is to enable early detection and save lives.
Research finds radically-altered subcellular activity in women carrying BRCA1/2 mutations, opening door to new preventative strategies and non-invasive test development. These changes were similar to those seen in ovarian cancer specimens, providing hope for reducing invasive surgery.
Researchers at Boston University School of Medicine found similarities in genetic and epigenetic alterations between breast and ovarian cancers. The study suggests that better understanding of these changes may lead to more effective chemotherapeutics and strategies to circumvent drug resistance.
Researchers discovered that immune T cells can overcome chemotherapy resistance in ovarian cancer by outsmarting fibroblasts. By boosting these immune cells, the tumor cells begin to die off, suggesting a new approach to treating ovarian cancer.
A new approach could help women of reproductive age preserve their fertility during cancer treatment by targeting DNA damage response in oocytes. This method has shown promise in animal models and may prevent premature ovarian insufficiency and infertility.
Dr. Nita Maihle is leading a national DOD initiative to support early career ovarian cancer investigators. The program aims to foster team science and improve understanding of the disease. With a focus on secretory cells that line the fallopian tubes, researchers hope to develop targeted therapies for this deadly form of cancer.
A new study published in Cell Reports identifies microRNA molecule miR551b as a promising candidate biomarker and therapeutic target for treating ovarian cancers. The research found that targeting miR551b expression could block STAT3 activity, offering potential for treating the most common and deadly form of ovarian cancer.
A new study by researchers at the University of Pennsylvania's Abramson Cancer Center found that testing non-breast cancer genes in high-risk women does not add clinical benefit. The study analyzed a large panel of genes and found that many variants were of uncertain significance, adding complexity to genetic counseling.
A study of 36 women found nearly all carried cancer-associated gene mutations, suggesting high accuracy and sensitivity for detecting ovarian cancer. Duplex sequencing technology can identify low-frequency cancer-like mutations, potentially leading to early detection and treatment.
A study published in Human Reproduction found that women with BRCA1 gene mutations have lower levels of anti-Müllerian hormone, indicating reduced ovarian reserves. This may impact fertility and suggest a need for earlier pregnancy planning.
A Phase 1/2 clinical trial is being conducted to evaluate the combination of MedImmune's durvalumab and VentiRx's motolimod in locally advanced or recurrent ovarian cancers. The study aims to assess the safety and efficacy of the combination, with a focus on enhancing anti-tumor immune responses.
Researchers have discovered a molecular fingerprint of some deadly cancers, including a genomic configuration called the tandem duplicator phenotype (TDP) that is enriched in triple-negative breast cancer and other types. This TDP is sensitive to cisplatin chemotherapy and can be scored using a genome-based formula.
A study presented at the 2016 USCAP Conference found that HER4 expression is associated with chemotherapy resistance and a lower survival rate in ovarian serous cancer patients. The research, led by Moffitt Cancer Center pathologists, suggests that HER4 may be a prognostic and potentially predictive marker for this type of cancer.
Researchers discover small peptides psaptides that can force tumors to regress by stimulating an anti-angiogenic response in healthy tissues. Psaptides mimic the naturally occurring human protein prosaposin, which stimulates immune cells to produce a potent anti-inflammatory protein called thrombospondin-1.
A multicentre study found type 1 diabetes associated with higher cancer incidence, especially for cancers of the stomach, liver, pancreas, endometrium, ovary, and kidney. Women with type 1 diabetes had a smaller but still significant increased risk compared to men.
Researchers at St. Joseph's Hospital and Medical Center found that a standard front-line treatment for advanced ovarian cancer should involve every three week chemotherapy with carboplatin, paclitaxel plus bevacizumab, or weekly dose intense paclitaxel without bevacizumab
A study at The Wistar Institute revealed that Satb1 expression is required for proper immune response, but its prolonged presence drives immunosuppressive behavior. Silencing Satb1 in tumor-associated dendritic cells boosted T-cell activation and reduced inflammation.
The Independent Data Monitoring Committee has recommended continuing the Phase III trial with PM1183 due to positive safety data from the first 80 patients. The trial assesses PM1183's efficacy compared to standard treatments for platinum-resistant ovarian cancer.
Researchers argue for greater support and research to help women make informed decisions about preventive mastectomies and ovary removal. The procedures can significantly reduce cancer risk but also carry risks and emotional challenges.
A study by Yale University researchers found that very few women undergo bilateral salpingectomy with ovarian conservation during hysterectomies for non-cancerous conditions. The procedure may help protect against ovarian cancer and preserve hormonal levels, but its use varies widely among hospitals across the US.